138 related articles for article (PubMed ID: 38396737)
61. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
62. Renal cell carcinoma.
Hsieh JJ; Purdue MP; Signoretti S; Swanton C; Albiges L; Schmidinger M; Heng DY; Larkin J; Ficarra V
Nat Rev Dis Primers; 2017 Mar; 3():17009. PubMed ID: 28276433
[TBL] [Abstract][Full Text] [Related]
63. Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE; Boothman DA; Fattah FJ; Dong Y; Zhu H; Skelton RA; Priddy LL; Vo P; Dowell JE; Sarode V; Leff R; Meek C; Xie Y; Schiller JH
Lung Cancer; 2015 Dec; 90(3):534-41. PubMed ID: 26474959
[TBL] [Abstract][Full Text] [Related]
64. The dual role of iNOS in cancer.
Vannini F; Kashfi K; Nath N
Redox Biol; 2015 Dec; 6():334-343. PubMed ID: 26335399
[TBL] [Abstract][Full Text] [Related]
65. Vorinostat-An Overview.
Bubna AK
Indian J Dermatol; 2015; 60(4):419. PubMed ID: 26288427
[TBL] [Abstract][Full Text] [Related]
66. Minnelide, a novel drug for pancreatic and liver cancer.
Banerjee S; Saluja A
Pancreatology; 2015 Jul; 15(4 Suppl):S39-43. PubMed ID: 26122306
[TBL] [Abstract][Full Text] [Related]
67. The hypoxic tumor microenvironment: A driving force for breast cancer progression.
Semenza GL
Biochim Biophys Acta; 2016 Mar; 1863(3):382-391. PubMed ID: 26079100
[TBL] [Abstract][Full Text] [Related]
68. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer.
Zhang W; Shi X; Peng Y; Wu M; Zhang P; Xie R; Wu Y; Yan Q; Liu S; Wang J
PLoS One; 2015; 10(6):e0129603. PubMed ID: 26057751
[TBL] [Abstract][Full Text] [Related]
69. Progress on hypoxia-inducible factor-3: Its structure, gene regulation and biological function (Review).
Yang SL; Wu C; Xiong ZF; Fang X
Mol Med Rep; 2015 Aug; 12(2):2411-6. PubMed ID: 25936862
[TBL] [Abstract][Full Text] [Related]
70. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
Krug LM; Kindler HL; Calvert H; Manegold C; Tsao AS; Fennell D; Öhman R; Plummer R; Eberhardt WE; Fukuoka K; Gaafar RM; Lafitte JJ; Hillerdal G; Chu Q; Buikhuisen WA; Lubiniecki GM; Sun X; Smith M; Baas P
Lancet Oncol; 2015 Apr; 16(4):447-56. PubMed ID: 25800891
[TBL] [Abstract][Full Text] [Related]
71. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.
Courtnay R; Ngo DC; Malik N; Ververis K; Tortorella SM; Karagiannis TC
Mol Biol Rep; 2015 Apr; 42(4):841-51. PubMed ID: 25689954
[TBL] [Abstract][Full Text] [Related]
72. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
Andreu-Vieyra CV; Berenson JR
Ther Adv Hematol; 2014 Dec; 5(6):197-210. PubMed ID: 25469210
[TBL] [Abstract][Full Text] [Related]
73. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
74. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
[TBL] [Abstract][Full Text] [Related]
75. Erasers of histone acetylation: the histone deacetylase enzymes.
Seto E; Yoshida M
Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018713. PubMed ID: 24691964
[TBL] [Abstract][Full Text] [Related]
76. Phase II trial of vorinostat in advanced melanoma.
Haas NB; Quirt I; Hotte S; McWhirter E; Polintan R; Litwin S; Adams PD; McBryan T; Wang L; Martin LP; vonMehren M; Alpaugh RK; Zweibel J; Oza A
Invest New Drugs; 2014 Jun; 32(3):526-34. PubMed ID: 24464266
[TBL] [Abstract][Full Text] [Related]
77. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
Jeong W; Rapisarda A; Park SR; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Cancer Chemother Pharmacol; 2014 Feb; 73(2):343-8. PubMed ID: 24292632
[TBL] [Abstract][Full Text] [Related]
78. Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Jeong W; Park SR; Rapisarda A; Fer N; Kinders RJ; Chen A; Melillo G; Turkbey B; Steinberg SM; Choyke P; Doroshow JH; Kummar S
Invest New Drugs; 2014 Apr; 32(2):340-6. PubMed ID: 24242862
[TBL] [Abstract][Full Text] [Related]
79. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Garrett CR; Bekaii-Saab TS; Ryan T; Fisher GA; Clive S; Kavan P; Shacham-Shmueli E; Buchbinder A; Goldberg RM
Cancer; 2013 Dec; 119(24):4223-30. PubMed ID: 24105075
[TBL] [Abstract][Full Text] [Related]
80. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
Haigentz M; Kim M; Sarta C; Lin J; Keresztes RS; Culliney B; Gaba AG; Smith RV; Shapiro GI; Chirieac LR; Mariadason JM; Belbin TJ; Greally JM; Wright JJ; Haddad RI
Oral Oncol; 2012 Dec; 48(12):1281-8. PubMed ID: 22748449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
